Skip to Main content Skip to Navigation
Journal articles

Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses

Abstract : STAT5 transcription factors are frequently activated in hematopoietic neoplasms and are targets of various tyrosine kinase oncogenes. Evidences for a crosstalk between STAT5 and reactive oxygen species (ROS) metabolism have recently emerged but mechanisms involved in STAT5-mediated regulation of ROS still remain elusive. We demonstrate that sustained activation of STAT5 induced by Bcr-Abl in chronic myeloid leukemia (CML) cells promotes ROS production by repressing expression of two antioxidant enzymes, catalase and glutaredoxin-1(Glrx1). Downregulation of catalase and Glrx1 expression was also observed in primary cells from CML patients. Catalase was shown not only to reduce ROS levels but also, to induce quiescence in Bcr-Abl-positive leukemia cells. Furthermore, reduction of STAT5 phosphorylation and upregulation of catalase and Glrx1 were also evidenced in leukemia cells co-cultured with bone marrow stromal cells to mimic a leukemic niche. This caused downregulation of ROS levels and enhancement of leukemic cell quiescence. These data support a role of persistent STAT5 signaling in the regulation of ROS production in myeloid leukemias and highlight the repression of antioxidant defenses as an important regulatory mechanism.
Complete list of metadata

https://hal-univ-tours.archives-ouvertes.fr/hal-02411729
Contributor : Fabrice Gouilleux Connect in order to contact the contributor
Submitted on : Friday, October 29, 2021 - 3:48:02 PM
Last modification on : Tuesday, January 11, 2022 - 5:56:12 PM

File

Oncogenic STAT5 signaling prom...
Publisher files allowed on an open archive

Identifiers

Collections

Citation

Jerome Bourgeais, Nicole Ishac, Magdalena Medrzycki, Marie Brachet-Botineau, Laura Desbourdes, et al.. Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses. Oncotarget, Impact journals, 2017, 8 (26), pp.41876-41889. ⟨10.18632/oncotarget.11480⟩. ⟨hal-02411729⟩

Share

Metrics

Les métriques sont temporairement indisponibles